TACSTD2 and exocrine pancreatic carcinoma: Furthermore, Nishimura et al (42) selected TROP2 as a molecular target for PIT, and utilized a newly developed humanized anti-TROP2 mAb conjugated to the photosensitizer IR700 (TROP2-IR700) for the treatment of pancreatic carcinoma and cholangiocarcinoma.